დასაწყისი · კატალოგი · პროფილი · ცხრილი
ჯანდაცვა BODY HANDBOOK
ჯანდაცვა · §660
Seasonal Influenza Vaccine
Catching the flu raises your odds of a heart attack about sixfold in the week after — an old plaque, calmly managed for years, tears open under the inflammatory hit. The ten-minute pharmacy shot, once a year, takes that window down. It also subtracts, in the years it lands, the week of fever and the three weeks of post-viral fog where even your hair hurts. The win is mostly invisible — a heart attack you don't have, a week your calendar doesn't lose — which is exactly why it gets skipped.
გააკეთე · ყოველწლიურად მტკიცებულება ზომიერი თავი ჯანდაცვა

In anyone with established heart disease, the shot cuts major cardiac events roughly a third in the year that follows — the same league as a high-intensity statin, for $30 and a needle. For everyone else, it cuts the odds of a typical-flu week — high fever, body-ache where even your hair hurts, three-week tail of fog — by about half. Free at most pharmacies, ten minutes, once a year. The catch: it's a chore, the events it prevented are invisible, and most people quietly skip the year they shouldn't have.

Your immune system runs on memory. The vaccine shows it a piece of this winter's flu virus — the spike protein that lets the virus latch onto cells in your nose and throat — and gives it three or four weeks to learn the shape. When the real virus shows up in February, antibodies that recognise that shape are already waiting at the door, and the infection is shorter, milder, or stopped at the threshold. That's the whole story.

Two details matter for the choice you'll actually make. First: the flu virus rewrites itself a little every year. The strain in your 2024 shot isn't the one circulating in 2026, which is why this is one of the few vaccines you have to re-take annually. Second: the immune response weakens with age. By 65, a standard dose generates strong antibody response in only about half of recipients (versus four out of five at 30), which is why the formulations marked high-dose, adjuvanted, or recombinant exist — they're built to compensate, and a 32,000-person trial in adults over 65 found high-dose cut symptomatic flu about a quarter further than the regular shot, plus measurable drops in serious pneumonia and hospitalisation.

What you're actually trading against

The flu people remember is the one that sent them to bed for a week. Fever 39+, body-ache where rolling over hurts, a cough that wakes the person sleeping next to you. You don't make decisions in that week; you wait it out. Then there's a tail — three weeks where stairs feel like a hill, where the meeting you used to run goes differently because you can't quite hold the thread. For working adults under 65 this is the central thing the vaccine subtracts from your odds: not every year, but the year it would have happened.

The piece most readers don't know sits in the cardiovascular tail. In the seven days after a confirmed flu infection, your odds of an acute heart attack go up roughly sixfold. The data is unusually clean — Ontario researchers cross-checked confirmed-flu cases against hospital admissions in the same patients in the years before and after, so each person is their own control. Strokes and heart-failure flares show the same pattern. The mechanism is straight inflammation: the fever-and-cytokine response that's clearing the virus also destabilises whatever atherosclerotic plaque you had quietly carrying around. For anyone with a coronary stent, prior heart attack, diabetes, or family history of early heart disease, that's the load-bearing reason to get the shot.

For the elderly and those with chronic lung or heart disease, the flu itself remains a leading cause of winter death — global modelling puts seasonal influenza at 290,000 to 650,000 respiratory deaths a year, with mortality climbing sharply past 75 Iuliano et al. 2018. The under-65 healthy reader is mostly buying themselves a calmer winter; the over-65 or cardiovascular-risk reader is buying something bigger.

How to actually do it

The whole protocol is: get the shot once a year, ideally between mid-September and the end of October, at a pharmacy. You don't need an appointment in most countries. The immune response peaks two to four weeks after the injection and tapers across the six months that follow, which is why the calendar matters — get it too early (August), and you've waned by February's peak; get it too late (January), and you may not have built up before exposure.

You'll need 10 to 20 minutes including the post-shot observation period. Expect a sore arm for 24-48 hours, occasionally a mild low-grade fever or fatigue the next day. Take the shot in your non-dominant arm if you can — you'll sleep on the other side more easily.

When to be careful

Egg allergy used to be a special-handling case; it isn't anymore. The 2024 guidance dropped the requirement for special precautions even with egg-grown vaccines — the egg-protein amount is too small to matter clinically ACIP 2024. If you have a moderate cold or fever the day of the appointment, push it a week. A genuine acute illness blunts the immune response and there's no upside to vaccinating while sick.

What people get wrong

"The shot gives you the flu." It can't. Every injectable version contains either inactivated virus or just the spike protein — no live, replicating virus, no ability to infect a cell. The sore arm and 24-hour low-grade fever some people get the day after are the immune system doing its job, not a mild flu. The nasal spray contains live attenuated virus but is engineered to grow only in the cool tissue of the nose; it doesn't cause systemic illness.

"I got the shot and still got sick." Usually true and usually not the flu. The same months that flu circulates — November through March — also carry RSV, common-cold coronaviruses, rhinovirus, and several others, all of which produce a fever-cough-aches week that feels like flu. A throat swab can tell them apart; without one, most "flu" by self-report is not flu. The few that are flu are usually shorter and milder for the vaccinated reader.

"I'm young and healthy, I don't need it." The individual benefit is smaller than for an elderly reader — but the studies in healthy adults still show roughly halving of confirmed-flu odds, and the community-protection argument is the other half of the case. Your shot makes you less likely to be the link in the chain that ends at the infant niece or grandmother on chemo who can't mount a vaccine response of their own.

"Last year's was good, so I'm covered." No. The virus shifts a little every year, and your antibody levels measurably wane across six months. The vaccine is reformulated each February for the coming winter; using it annually is the design.

Why it sometimes underperforms

Two reasons. First: strain mismatch. Public health authorities pick the strains in February, eight months before the season starts, and the H3N2 component drifts the fastest. In bad-match seasons like 2014-15, real-world effectiveness against confirmed flu dropped to roughly 19%. That's the floor, not the average — in better-matched years the pooled estimate is 50-60%.

Second: the egg problem. Most flu vaccines are grown in chicken eggs, a process that subtly mutates the virus's spike protein in ways that drift it away from the wild type. The H3N2 strain is most sensitive to this. The recombinant (Flublok) and cell-grown (Flucelvax) products skip eggs entirely and tend to perform better in H3N2-heavy years — worth asking for if you're choosing.

The reader-level takeaway: in a bad-match season, a vaccinated person who catches flu is still meaningfully less likely to be hospitalised than an unvaccinated one. The vaccine's protection against severe disease holds up better than its protection against any infection at all — even when antibody response doesn't quite match the spike, it usually still tempers severity.

Where the calculus shifts

Most adults are getting a real but modest individual benefit and a real community benefit. A few groups are getting something much larger, and the choice tips harder for them.

Adults 60+. The case is about as strong as adult preventive medicine gets. Your baseline risk of being hospitalised or killed by flu is higher; your standard-shot antibody response is weaker; and the enhanced products (high-dose, adjuvanted, recombinant) close most of that gap. The 32,000-person high-dose trial showed roughly a quarter fewer confirmed-flu cases plus measurable reductions in pneumonia and hospitalisation. Ask for one of the three enhanced products by name — pharmacies usually have them, but the default they hand you might not be one.

Anyone with cardiovascular disease. This is the group where the vaccine starts to look like a cardiac drug. The IAMI trial randomised heart-attack patients within 72 hours of their stent placement to flu vaccine or placebo and found 41% lower all-cause mortality at one year in the vaccinated arm Frobert et al. 2021. Across all the trials in coronary-disease patients, the consistent finding is roughly a third fewer major cardiac events in the year that follows Behrouzi et al. 2022. European and American cardiology guidelines now treat annual flu vaccination as standard secondary prevention after a heart attack — same status as a statin.

Pregnant women. Inactivated shot at any point in pregnancy. The infection itself is unusually rough during pregnancy (more hospitalisation, more pre-term delivery), and the antibodies cross the placenta — your shot in the third trimester protects the baby for the first six months of life, the months they can't be vaccinated themselves.

Healthcare workers and live-in carers. Your personal risk reduction is the same as any healthy adult's; the larger reason to do it is the patients and family members you'd otherwise transmit to during their treatment window. Most hospital systems make this mandatory, with reason.

What you actually get back

Most of it is invisible — the events you don't notice because they didn't happen. The honest shape:

Days after. A sore arm. The occasional mild fever the next morning. The decision is made; you move on.

The winter that follows. Across the population, vaccinated adults catch confirmed flu roughly half as often as unvaccinated ones — but the typical reader doesn't catch flu in any given year, so the felt benefit is mostly probabilistic. The year it pays out, it pays out big: the week of high fever and the three-week tail of fog you don't have to live through.

A year out, for the cardiovascular-risk reader. The clearest effect in the literature. A third fewer cardiac events at twelve months in anyone with a recent heart attack or established coronary disease Behrouzi et al. 2022. The phone call your cardiologist doesn't have to make to your family. The retirement that arrives intact instead of curtailed by a winter event everyone had been calmly managing the underlying risk for.

A decade in. For the over-65 reader, repeated annual vaccination across a decade is one of the few interventions that measurably shifts winter all-cause mortality at the population level DiazGranados et al. 2014. For the healthy 30-year-old, it's the absence of roughly half the bad winters you'd otherwise have had — and the moral relief of knowing the chain that runs from you to the people who can't get the shot stops a little shorter.

Adjacent things worth knowing

The flu shot is one of several adult vaccines that move the needle yearly or once-in-life — none of them substitutes for the others, and most readers under-do all of them. The COVID-19 booster runs on the same fall calendar; the two can be given at the same appointment, opposite arms. Over 50, the shingles vaccine (Shingrix, two doses, lifelong) is the single most under-prescribed adult vaccine for its impact. Over 65, the pneumococcal vaccines (PCV20 or PCV15+PPSV23) and the RSV vaccine are the natural companions to the annual flu shot. After 50 with any risk factor, the cardiovascular case for the flu shot becomes a cardiovascular case for understanding your apoB and your blood pressure too.

If you do catch flu despite the shot, the antivirals (oseltamivir, baloxavir) shorten the course by roughly a day if started within 48 hours of symptom onset — worth knowing about, especially if you're high risk; a different decision from the prevention question.

·
660